Atara Biotherapeutics Inc. (ATRA) CEO Isaac E. Ciechanover Sells 7,200 Shares of Stock
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,200 shares of the firm’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $19.36, for a total value of $139,392.00. Following the completion of the transaction, the chief executive officer now owns 229,136 shares in the company, valued at $4,436,072.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 20.23 on Wednesday. Atara Biotherapeutics Inc. has a one year low of $13.31 and a one year high of $45.80. The stock has a 50 day moving average price of $21.37 and a 200-day moving average price of $20.02. The company’s market capitalization is $582.85 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.05. On average, equities research analysts expect that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.
Several research analysts have recently issued reports on ATRA shares. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $23.00 to $16.00 in a research report on Thursday, September 15th. Citigroup Inc. raised their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research report on Friday, August 19th. Jefferies Group restated a “buy” rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a research report on Sunday, July 10th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Finally, Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $26.14.
Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in shares of Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock valued at $70,353,000 after buying an additional 720,313 shares during the period. Redmile Group LLC increased its position in shares of Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock valued at $54,226,000 after buying an additional 133,205 shares during the period. BlackRock Fund Advisors increased its position in shares of Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock valued at $20,572,000 after buying an additional 143,242 shares during the period. Bridger Management LLC bought a new position in shares of Atara Biotherapeutics during the first quarter valued at about $14,072,000. Finally, Vanguard Group Inc. increased its position in shares of Atara Biotherapeutics by 20.3% in the second quarter. Vanguard Group Inc. now owns 679,690 shares of the company’s stock valued at $15,300,000 after buying an additional 114,734 shares during the period. Institutional investors own 75.50% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.